Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and distribution of medicine for ophthalmic, neuropsychiatric and other applications in China. It also develops a pipeline of clinical and pre-clinical programs for ophthalmology, CNS, oncology, and common disease. The company was founded in 1996 and is based in Chengdu, China.
Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) - Total Liabilities
Latest total liabilities as of September 2025: CN¥719.98 Million CNY
Based on the latest financial reports, Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has total liabilities worth CN¥719.98 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Chengdu Kanghong Pharmaceuticals Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Chengdu Kanghong Pharmaceuticals Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Chengdu Kanghong Pharmaceuticals Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tompkins Financial Corporation
NYSE MKT:TMP
|
USA | $7.68 Billion |
|
Lier Chemical Co Ltd
SHE:002258
|
China | CN¥7.02 Billion |
|
Sabine Royalty Trust
NYSE:SBR
|
USA | $752.82K |
|
Endo, Inc.
OTCQX:NDOI
|
USA | $3.06 Billion |
|
Micro Tech Nanjing Co Ltd
SHG:688029
|
China | CN¥948.64 Million |
|
Lincoln Educational Services
NASDAQ:LINC
|
USA | $293.48 Million |
|
Pilot Corporation
OTCGREY:POGHF
|
USA | $32.34 Billion |
|
Bangchak Corporation Public Company Limited
BK:BCP-R
|
Thailand | ฿248.71 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Chengdu Kanghong Pharmaceuticals Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chengdu Kanghong Pharmaceuticals Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chengdu Kanghong Pharmaceuticals Group Co Ltd (2009–2024)
The table below shows the annual total liabilities of Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥695.07 Million | -3.16% |
| 2023-12-31 | CN¥717.76 Million | -11.81% |
| 2022-12-31 | CN¥813.85 Million | -4.37% |
| 2021-12-31 | CN¥851.08 Million | -31.66% |
| 2020-12-31 | CN¥1.25 Billion | +3.22% |
| 2019-12-31 | CN¥1.21 Billion | +8.60% |
| 2018-12-31 | CN¥1.11 Billion | +6.54% |
| 2017-12-31 | CN¥1.04 Billion | +22.20% |
| 2016-12-31 | CN¥853.27 Million | +126.82% |
| 2015-12-31 | CN¥376.19 Million | +14.30% |
| 2014-12-31 | CN¥329.11 Million | +7.66% |
| 2013-12-31 | CN¥305.69 Million | -18.57% |
| 2012-12-31 | CN¥375.39 Million | +4.39% |
| 2011-12-31 | CN¥359.58 Million | -1.81% |
| 2010-12-31 | CN¥366.21 Million | +29.07% |
| 2009-12-31 | CN¥283.73 Million | -- |